Silence Therapeutics

SLN · Nasdaq · United Kingdom

Share price · SLN

$19.82+5.72 (+40.57%) 3M

close as of 2026-11-18 · 24h delayed · vol 1.5M (0.4x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when SLN's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 19 Oct 2026+125.6%
  2. 10 Aug 2026+29.1%
  3. 22 Jul 2026+9.0%

    Nothing announced by SLN that day or the session before.

  4. 24 Jun 2026+26.0%
  5. 15 May 2026-14.4%

    Nothing announced by SLN that day or the session before.

  6. 15 Apr 2026+19.0%

    Nothing announced by SLN that day or the session before.

  7. 11 Mar 2026+11.3%

    Nothing announced by SLN that day or the session before.

  8. 6 Mar 2026+13.3%
  9. 2 Mar 2026+9.9%

    Nothing announced by SLN that day or the session before.

  10. 17 Feb 2026+12.6%

Share of unusual movement by asset

For each asset, the share of SLN's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Zerlasiran
events and moves
1shown from 8 days
Assets with fewer than 8 event days, together—6%
Other company news (earnings, financing, releases naming no asset)—60%
Sessions with no dated event—34%

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Phase 2
LPA gene / apolipoprotein(a) mRNARNA / oligonucleotide
Atherosclerotic Cardiovascular Disease

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Financial reports

Quarterly & interim (9)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3$0$9.3M$248M+ $0 short-term inv.$12M-$13M operating cash flowreport ↗
View 8 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2$0$9.2M$72M+ $0 short-term inv.$12M$1.5M operating cash flowreport ↗
2026-Q1$0.4M$9.1M$5.7M+ $64M short-term inv.$15M-$16M operating cash flowreport ↗
2025-Q3$0.2M$21M$82M+ $20M short-term inv.$21M-$11M operating cash flowreport ↗
2025-Q2$0.2M$18M$42M+ $72M short-term inv.$27M-$22M operating cash flowreport ↗
2025-Q1$0.1M$21M$65M+ $72M short-term inv.$29M-$12M operating cash flowreport ↗
2024-Q3$1.5M$20M—$36M-$26M operating cash flowreport ↗
2024-Q2$0.8M$14M—$20M-$5.4M operating cash flowreport ↗
2024-Q1$16M$12M—$2.3M-$9.1M operating cash flowreport ↗

Annual history (4 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$0.6M$68M$11M+ $74M short-term inv.$22M-$62M operating cash flowreport ↗

Silence Therapeutics reported full-year 2025 revenue of $0.56M, down 98.7% YoY, with R&D spend of $67.75M, down 0.2% YoY. Cash and cash equivalents were $11.28M, and total cash, cash equivalents, and short-term investments were $85.1M at year-end. The company reported a net loss of $88.61M, or $0.63 per basic and diluted share.

Management reiterated that topline results for the Phase 2 SANRECO trial of divesiran in polycythemia vera remain on track for the third quarter of 2026, while zerlasiran is positioned as a Phase 3-ready program for potential partnering. AstraZeneca notified Silence that it will not advance SLN312 beyond Phase 1, returning global rights to Silence, and preclinical data for SLN365 and SLN098 are expected in the second quarter of 2026. Corporate updates included an interim principal executive officer appointment and board changes.

View 3 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$43M$68M$121M+ $26M short-term inv.$11M-$68M operating cash flowreport ↗
2023-FY$32M$57M$69M$14M-$49M operating cash flowreport ↗
2022-FY$22M$44M—$13M-$57M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases (—), 0 sales (—). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-08-10Griffiths Richard Ian · 10% ownerOpen-market sale (derivative)2,792,826——Form 4
2026-08-10Griffiths Richard Ian · 10% ownerOpen-market sale (derivative)100,000——Form 4
2026-08-10Griffiths Richard Ian · 10% ownerOpen-market sale (derivative)50,000——Form 4
2026-08-10Griffiths Richard Ian · 10% ownerOpen-market sale (derivative)3,500——Form 4
2026-08-10Griffiths Richard Ian · 10% ownerOpen-market sale (derivative)800,000——Form 4
2026-08-10Griffiths Richard Ian · 10% ownerOpen-market sale (derivative)382,000——Form 4
2026-08-10Griffiths Richard Ian · 10% ownerOpen-market sale (derivative)470,820——Form 4
2026-08-10Griffiths Richard Ian · 10% ownerOpen-market sale (derivative)605,174——Form 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 56 reporting institutions held 19.9M shares ($100.5M, 14.1% of shares outstanding).

#InstitutionSharesValue
1TCG Crossover Management, LLC3,033,560$16.0M
2Siren, L.L.C.2,911,438$15.3M
3Redmile Group, LLC2,164,777$11.4M
4Nantahala Capital Management, LLC2,146,731$11.3M
5CITADEL ADVISORS LLC1,234,807$6.5M
6MILLENNIUM MANAGEMENT LLC1,074,191$5.7M
7GREAT POINT PARTNERS LLC1,020,489$5.4M
8Nextech Invest, Ltd.952,400$5.0M
9Tetragon Partners GP Ltd630,161$3.3M
105AM Venture Management, LLC476,200$2.5M
11Ikarian Capital, LLC865,784$1.7M
12Jones Hill Capital LP301,604$1.6M
13UBS Group AG246,937$1.3M
14BOOTHBAY FUND MANAGEMENT, LLC209,088$1.1M
15BlackRock, Inc.204,777$1.1M